Search Within

Ghassan Abou-Alfa

Formats
  1. Meeting Abstract (262)
  2. Journal Article (246)
  3. Review (27)
  4. Book Section (16)
  5. Editorial (8)
  6. Book Whole (4)
  7. Correspondence (4)
  8. Guidelines (4)
  9. Miscellaneous (3)
  10. Research Letter (1)
Groups
  1. Department of Medicine (575)
  2. Gastrointestinal Oncology Service (575)
  3. Solid Tumor Oncology Division (575)
  4. Center for Pancreatic Cancer Research (215)
  5. Epidemiology and Biostatistics (122)
  6. Surgery (103)

More Groups

People
  1. Eileen O'Reilly (156)
  2. James Harding (130)
  3. William Jarnagin (66)
  4. Marinela Capanu (65)
  5. Leonard Saltz (55)
  6. Imane El Dika (54)

More People

Years
  1. 2025 (20)
  2. 2024 (52)
  3. 2023 (48)
  4. 2022 (53)
  5. 2021 (46)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (166)
  2. Annals of Oncology (53)
  3. Gastrointestinal Cancer Research (21)
  4. Oncology Research and Treatment (18)
  5. Annals of Surgical Oncology (15)
  6. Cancer (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (182)
  2. Oxford University Press (65)
  3. Springer (36)
  4. Wiley Blackwell (30)
  5. Elsevier Inc. (25)
  6. Elsevier Science, Inc. (24)

More Publishers

Results (575)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    Yau, T.; Meyer, T.; Kelley, R. K.; Mangeshkar, M.; Cheng, A. L.; El-Khoueiry, A. B.; Abou-Alfa, G. K.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Chan, S. L.; Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H. J.; Kim, S.; Lin, Z. Z.; Youkstetter, J.; Sen, S.; Cheng, A. L.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes
    Journal Article

    Lowery, M. A.; Goff, L. W.; Keenan, B. P.; Jordan, E.; Wang, R.; Bocobo, A. G.; Chou, J. F.; O’Reilly, E. M.; Harding, J. J.; Kemeny, N.; more...
    Cancer (2019)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    Parnis, F.; Rimassa, L.; Kelley, R. K.; Meyer, T.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Blanc, J. F.; Lim, H. Y.; Tran, A.; more...
    Asia-Pacific Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
    Meeting Abstract

    Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
    Meeting Abstract

    Abou-Alfa, G. K.; Macarulla Mercade, T.; Javle, M.; Kelley, R. K.; Lubner, S.; Adeva, J.; Cleary, J. M.; Catenacci, D. V.; Borad, M. J.; Bridgewater, J. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients
    Meeting Abstract

    Awada, A. H.; Harding, J. J.; Kotecki, N.; Aftimos, P. G.; Decaens, T.; Dreyer, C.; Ansaldi, C.; Rachid, M.; Serdjebi, C.; Halfon, P.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
    Meeting Abstract

    Freemantle, N.; Abou-Alfa, G. K.; Cheng, A. L.; Kelley, R. K.; Valcheva, V.; Benzaghou, F.; Mollon, P.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    Rimassa, L.; Kelley, R. K.; Meyer, T.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Blanc, J. F.; Lim, H. Y.; Tran, A.; Borgman-Hagey, A. E.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    Meyer, T.; Kelley, R. K.; Mangeshkar, M.; Cheng, A. L.; El-Khoueiry, A. B.; Abou-Alfa, G. K.
    Annals of Oncology (2019)

    Fulltext@MSK | Save